AACR Names T-Cell ALL Researcher as a 2023 Next Gen Star
By Anastasia Tikhonova, PhD - Last Updated: May 9, 2023Anastasia Tikhonova, PhD, was named a 2023 NextGen Star by the American Association for Cancer Research (AACR). Dr. Tikhonova, whose research is in T-cell acute lymphoblastic leukemia (ALL), talks about the honor of being awarded the title in this video interview.
Advertisement
Post Tags:AACR 2023
Advertisement
Related Posts
Measurable residual disease has a prominent role in risk assessment, prognosis, and management decisions in T-ALL and B-ALL.
Melody Smith, MD, MS, shares data on burnout in hematologist oncologists, why it occurs, and how to prevent it.
CTD402 will be studied in a single-arm, open-label, phase 1b/2 trial with a simplified dose-finding design.
The approval is based on the E1910 trial, which compared blinatumomab and consolidation chemotherapy with chemotherapy alone.
Therapy also in development for T-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and mantle cell lymphoma.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.